Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867369 · ClinicalTrials.gov registry record · Phase 4
Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT04867369 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 160 participants.
The verdict
NCT04867369, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.
Interventions
- DRUG Bupivacaine 20mL 0.5%
- DRUG Bupivacaine 20mL 0.25%
- DRUG Bupivacaine up to 15mL 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2023-11-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04867369
The ClinicalTrials.gov registry entry for NCT04867369 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bupivacaine 20mL 0.5% is the first listed.
NCT04867369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04867369 about?
NCT04867369 is a clinical study titled "Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis". A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.
What is the current status of trial NCT04867369?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2021-07-14. Estimated completion is 2023-11-11.
What interventions are being tested in trial NCT04867369?
The interventions under investigation include: Bupivacaine 20mL 0.5% (DRUG), Bupivacaine 20mL 0.25% (DRUG), Bupivacaine up to 15mL 0.25% (DRUG).
Who is sponsoring clinical trial NCT04867369?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.